Frequently Asked Questions

Our client, an Illinois pharmacy, was targeted by a major PBM with cease-and-desist notices that alleged violations of the Provider Manual. Although the pharmacy responded to the PBM in an attempt to address the allegations, the PBM terminated the pharmacy anyway. At that point, the pharmacy retained our firm, and we immediately sprung into action to reverse the impending termination on short notice.

Successful PBM Appeals Often Require Legal Advocacy

Throughout the appeal process, HLA's experienced healthcare defense attorneys meticulously presented documentation and legal analysis that systematically addressed the PBM's alleged violations and demonstrated that either no violation occurred, or that any violation was an isolated error that did not support termination. Specifically, we combine our arguments on the facts with extensive legal research and analysis demonstrating why the PBM is not entitled to terminate the agreement at issue under relevant federal, state, and common law.

HLA's Legal Methods are Tailored to Each Case

Our method for approaching these cases is to present the client's narrative and facts in a convincing and compelling fashion, relying on our subject matter expertise, to explain why vague statements in a manual do not prohibit or apply to the facts at issue. In addition, it is important to address the PBM's concern that the conduct at issue not recur. Accordingly, because our firm employs the former Chief Compliance Officer of United Health Group, we are in a position to recommend tailored compliance strategies that the PBMs will accept in mitigation.

As part of our work in this case, our healthcare compliance specialists implemented new standard operating procedures, updated policies, and retrained staff, convincing the PBM to reinstate the pharmacy based on improved compliance protocols. This often tips the balance towards reinstatement.

Network Termination Can be Avoided

We work on many network appeals, so we can be efficient in budgeting to achieve desirable results. In this case, the pharmacy was about to be sold to a new owner, and the network termination obviously destroyed a lot of that value. By winning network reinstatement on appeal, we were able to dramatically increase the owner's return on investment. Nonetheless, if you are at risk of termination, the earlier you involve qualified counsel, the better. We are always available to help.

MORE ARTICLES BY CATEGORY

Get a Free Case REVIEW

100% Confidential & Secure. Your details are safe with us.

We'll speak soon!

In the meantime, why not find out more about us or visit our blog.

Alternatively, give us a call at (800) 345 - 4125

Oops! Something went wrong while submitting the form.

HLA's Diana Yastrovskaya Featured in PBM Discussion for WJAC

The feature underscores HLA’s mission to elevate thought leadership within the healthcare space and provide trusted expertise on issues that directly impact patients, providers, and policymakers.

Read More >>

By Appointment Only: How DME Suppliers Can Prevent Unexpected DME License Revocations

DME suppliers can prevent unexpected and costly license revocations by strategically applying with a "By Appointment Only" designation. This article explores the common compliance trap of failing unannounced site visits due to conflicts between standard pharmacy operating hours and Medicare's "posted hours" requirement for DME suppliers. "By Appointment Only" status is a crucial safeguard, which suppliers can take to implement to protect their DME billing privileges.

Read More >>

Resolving Prescription “Red Flags” Is No Longer Optional: Federal Scrutiny Tightens on Controlled-Substance Dispensing

Pharmacists must resolve “red flags” under the Controlled Substances Act’s corresponding-responsibility requirements before dispensing controlled substances. Overlooking warning signs, such as cash-paid, high-dose opioid prescriptions—can now trigger False Claims Act liability and massive penalties, as demonstrated by Walgreens’ $350 million settlement in April 2025.

Read More >>

9th Circuit’s Landmark EKRA Ruling—What Providers Should Know

On July 11, 2025, the 9th Circuit upheld a laboratory operator’s convictions for violating EKRA by paying marketing agents to mislead providers into providing patient referrals for medically unnecessary blood tests. In this article, we analyze the 9th Circuit’s ruling and what it means for the future of EKRA enforcement.

Read More >>